Share This Page
Drug Price Trends for CARBIDOPA-LEVO
✉ Email this page to a colleague

Average Pharmacy Cost for CARBIDOPA-LEVO
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
CARBIDOPA-LEVODOPA 10-100 TAB | 75907-0022-01 | 0.08642 | EACH | 2025-01-22 |
CARBIDOPA-LEVODOPA 25-250 TAB | 75907-0021-01 | 0.11726 | EACH | 2025-01-22 |
CARBIDOPA-LEVODOPA 25-100 TAB | 75907-0020-10 | 0.07629 | EACH | 2025-01-22 |
CARBIDOPA-LEVODOPA 25-100 TAB | 75907-0020-05 | 0.07629 | EACH | 2025-01-22 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Carbidopa-Levodopa
Introduction to Carbidopa-Levodopa
Carbidopa-Levodopa is a combination medication primarily used to manage the symptoms of Parkinson's disease. Levodopa, also known as L-DOPA, is a precursor to dopamine, a neurotransmitter essential for movement control, while carbidopa inhibits the conversion of levodopa to dopamine outside the brain, thereby increasing the availability of levodopa in the central nervous system[1][4].
Market Size and Growth
The global levodopa market, which includes carbidopa-levodopa combinations, was valued at $1.7 billion in 2022 and is projected to reach $2.9 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.1% from 2023 to 2032. This growth is largely driven by the increasing prevalence of Parkinson's disease, a condition characterized by the loss of dopamine-producing neurons in the brain[1].
Market Dynamics
The rise in the aging population and longer life expectancy are key factors contributing to the increased prevalence of Parkinson's disease. This demographic trend has created a significant demand for effective treatments, with levodopa being a primary treatment option. The market is also influenced by advancements in drug delivery systems, such as extended-release formulations and continuous infusion systems, which enhance treatment efficacy and patient compliance[1][4].
Key Market Players
Major players in the carbidopa-levodopa market include Novartis AG, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Impax Laboratories Inc., Pfizer Inc., UCB SA, Sun Pharmaceutical Industries Ltd., and Mylan NV. These companies are investing in research and development to improve treatment options and expand their market share[1].
Regional Market Analysis
North America is expected to dominate the global levodopa market, driven by the approval of new products by the U.S. Food and Drug Administration (FDA). For instance, the FDA approved Duopa, an extended-release oral formulation of carbidopa/levodopa, in 2015. This gel formulation is administered using a portable infusion pump, providing continuous release of the medication over 16 hours[4].
Formulations and Pricing
Carbidopa-levodopa is available in various formulations, including immediate-release tablets, extended-release tablets, and disintegrating tablets.
- Immediate-Release Tablets: The cost for carbidopa/levodopa (25 mg-100 mg) oral tablets can range from $14.27 to $15.94 for a supply of 30 tablets, depending on the dosage and pharmacy[2].
- Extended-Release Tablets: The price for carbidopa/levodopa extended-release tablets (25 mg-100 mg) starts from $17.95 for 30 tablets[2].
- Disintegrating Tablets: The cost for carbidopa/levodopa disintegrating tablets (25 mg-100 mg) can range from $96.24 to $110.83 for 100 tablets[2].
Combination Therapies
Carbidopa-levodopa is often combined with other medications to enhance its efficacy and reduce side effects. For example, carbidopa/entacapone/levodopa combinations are available, with prices ranging from $129.49 to $328.32 for a supply of 100 tablets, depending on the dosage[5].
Future Outlook
The market for carbidopa-levodopa is expected to continue growing due to several factors:
- Technological Advancements: Ongoing research into new drug delivery systems and disease-modifying treatments will improve treatment efficacy and patient outcomes.
- Emerging Markets: Asia-Pacific is projected to provide significant business opportunities for the levodopa market in the future.
- Personalized Medicine: Increased focus on personalized medicine will lead to more tailored treatment options for Parkinson's disease patients[1][4].
Challenges and Opportunities
While the market for carbidopa-levodopa is growing, there are challenges to consider:
- Side Effects: Long-term use of levodopa can lead to complications such as dyskinesias, which necessitates the development of new treatments with fewer side effects.
- Regulatory Approvals: The approval process for new formulations and combination therapies can be lengthy and stringent, affecting market entry and growth.
However, these challenges also present opportunities for innovation and growth. For instance, the development of new products like AbbVie’s ABBV-951, which is forecast to have significant market uptake, highlights the potential for improved treatment options[3].
Key Takeaways
- The global levodopa market, including carbidopa-levodopa combinations, is projected to reach $2.9 billion by 2032.
- The market is driven by the increasing prevalence of Parkinson's disease and advancements in drug delivery systems.
- North America is expected to dominate the market due to FDA approvals of new products.
- Various formulations of carbidopa-levodopa are available, with prices varying based on the type and dosage.
- Future growth will be influenced by technological advancements, emerging markets, and a focus on personalized medicine.
FAQs
1. What is the primary use of carbidopa-levodopa? Carbidopa-levodopa is primarily used to manage the symptoms of Parkinson's disease by replenishing dopamine levels in the brain.
2. What is the projected market size of the levodopa market by 2032? The global levodopa market is projected to reach $2.9 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032[1].
3. Which region is expected to dominate the carbidopa-levodopa market? North America is expected to dominate the global levodopa market, driven by FDA approvals of new products[4].
4. What are the different formulations of carbidopa-levodopa available? Carbidopa-levodopa is available in immediate-release tablets, extended-release tablets, disintegrating tablets, and combination therapies with other medications like entacapone[2][5].
5. What are the key factors driving the growth of the carbidopa-levodopa market? The growth of the carbidopa-levodopa market is driven by the increasing prevalence of Parkinson's disease, advancements in drug delivery systems, and emerging markets[1][4].
Sources
- Allied Market Research - Levodopa Market Size, Growth Analysis | Forecast - 2032
- Drugs.com - Carbidopa/levodopa Prices, Coupons, Copay Cards & Patient Assistance Programs
- GlobalData - Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029
- Coherent Market Insights - Levodopa Market - Companies, Size, Share & Research Analysis
- Drugs.com - Carbidopa/entacapone/levodopa Prices, Coupons, Copay Cards & Patient Assistance Programs
More… ↓